As VP of Translational Science and Experimental Medicine (TSEM) for 呼吸与免疫学 (R&在澳门葡京网赌游戏，我是R的一部分&领导团队遍布英国、瑞典和美国. I designed and launched TSEM to provide a roadmap from novel targets to disease pathology and biomarkers, 从一开始就有精准医疗, emphasising the importance of understanding the heterogeneity of common chronic disease.

Already we have a number of molecules in clinical development where we are actively developing what will be some of the first examples of precision medicine for common chronic disease.

以前, as Global Head of Genomics Portfolio in 澳门葡京网赌游戏’s Centre for Genomics Research, I played a pivotal role in securing the $400+ million investment to integrate genome sequence and clinical data from up to two million patients. Other business-critical deliveries have included 澳门葡京网赌游戏’s first respiratory diagnostic achieving EU CE-IVD certification in December 2018, and FDA clearance for a Point of Care (PoC) serum uric acid meter to monitor the effectiveness of urate lowering therapies.

I completed my PhD in molecular genetics from the University of Liverpool and I have published over 40 peer-reviewed articles, 最近发表在《澳门葡京网赌游戏》上, 《澳门葡京赌博游戏》和《澳门葡京网赌游戏》.

It is a privilege to have the opportunity to apply strong science with many of the talented scientists and teams at 澳门葡京网赌游戏 to bring life changing medicines to improve patients’ lives.

亚当·普拉特博士 转化科学和实验医学副总裁兼主管, 呼吸 & 免疫学、澳门葡京网赌游戏

Award

2017年呼吸PoC诊断CEO奖

Award

2017年度最佳CEO奖，实现科学领导力

Award

2016 Senior Scientist IMED Award – Development of 呼吸 PoC Diagnostic

Award

2016年IMED认可奖-基因组战略

主要成就

转化科学和实验医学副总裁兼主管, 呼吸与免疫学, 澳门葡京网赌游戏

开发嗜酸性呼吸系统疾病PoC测试原型, which will become 澳门葡京网赌游戏’s first POC diagnostic for respiratory disease.

设计和启动目标与转化科学, IMED RIA的一个新组织, 提供从目标调节到疾病病理的路线图.

Co–establishing the 澳门葡京网赌游戏 Genomics Initiative and Centre for Genomics Research (CGR). This initiative involves integrating genome sequence and clinical data from up to two million patients from 澳门葡京网赌游戏’s clinical trials and key international partnerships.

  特色的出版物

外显子组测序在肾脏疾病诊断中的应用.

Groopman E. 等, 普拉特,*, 戈尔茨坦,D.B.加拉维，A.G. (2018) 新英格兰医学杂志， doi: 10.1056 / NEJMoa1806891

*论文中注明的共同资深作者

精准医疗时代的药物发展.

杜格尔S, 普拉特一, Goldstein D， (2018); 药物发现 17 (3):183-196.

点护理尿酸检测仪的分析比较.

Paraskos J, Berke Z, Cook J, Miner JN, Braddock M, 普拉特一, Hughes G, (2016) 分子诊断学专家评论. 16(3):373-382. DOI: 10.1586/14737159.2016.1134326.

 

类风湿关节炎:个体化保健的案例?

普拉特 A, Karsdal M A, Bay-Jensen A C, (2014), 关节炎的护理与研究 66(9):1273-80.

RET易位的回顾性分析, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies.

普拉特一, Morten J, Ji Q, 艾文P, 沃马克C, Su X, Donald E, 灰色N, 读J, 绑架G, Blockley L, Cresswell C, 戴尔的一个, 戴维斯一个, 张T, 风扇年代, Fu H, Gladwin一, 哈罗德G, 史蒂文斯J, 威廉姆斯V, Ye Q, 郑L, 德波尔R, Herbst RS, 李JS, Vasselli J, (2015), 1. BMC癌症. 15(1):171.



Translational biomarkers and ex vivo models of joint tissues as a translational tool for drug development in rheumatoid arthritis.

Kjelgaard-Petersen CF, 普拉特一, 布拉多克B, 詹金斯米, 穆萨K, 格雷厄姆E, 基勒年代, Slynn G, Weinblatt我, Karsdal马, Bay-Jensen交流, (2018), 关节炎及风湿病学, 70(9):1419-1428

Serological biomarkers of joint tissue turnover predict tocilizumab response at baseline.

Bay-Jensen交流, Byrjalsen I, Siebuhr AS, Christiansen C, 普拉特一, Karsdal马, (2014), 临床风湿病杂志. 20(6):332-335.

IL-6 pathway-driven investigation of response to IL-6 receptor inhibition in rheumatoid arthritis.

王J, 普拉特一, Benayed R, Germer完成的年代, Lei G, 瑞芭C, Benayed R, Kenwright一, 海明斯一个, 马丁·米, 他啊, (2013), 英国医学杂志 2013;3:e003199. doi: 10.1136 / bmjopen - 2013 - 003199.

Serological identification of fast progressors of structural damage with rheumatoid arthritis.

Siebuhr AS, Bay-Jensen交流, Leeming D.J, 普拉特一, Byrjalsen I, Christiansen C, van de Heijde D, Karsdal马 (2013), 关节炎研究 & 治疗 15: R86 doi: 10.1186/ar4266.

Genome-wide association analysis implicates the involvement of eight loci with response to tocilizumab for the treatment of rheumatoid arthritis.

王J, 邦萨尔在, 马丁·米, Germer完成的年代, Benayed R, Essioux L, 李JS, Begovich一, 海明斯一个, Kenwright一, 泰勒柯, Upmanyu R, 卡特勒P, 他啊, 马J, 克里斯拉, 普拉特一, (2012), 药物基因组学杂志 13:235-241.

IL-6 Receptor Inhibition Positively Modulates Bone Balance in Rheumatoid Arthritis Patients with an Inadequate Response to Anti-Tumor Necrosis Factor 治疗: Biochemical Marker Analysis of Bone Metabolism in the tocilizumab RADIATE Study.

Karsdal马, Schett G, Emery P, 他啊, Byrjalsen I, Kenwright一, Bay-Jensen交流, 普拉特一, (2012), 关节炎及风湿病研讨会 42(2):131-9.

Genetic variation in UGT1A1 typical of Gilbert syndrome is associated with unconjugated hyperbilirubinemia in patients receiving tocilizumab.

李JS, 王J, 马丁·米, Germer完成的年代, Kenwright一, Benayed R, Spleiss O, 普拉特一, Pilson R, 海明斯一个, Weinblatt我, Kaplowitz N, Krasnow J, (2011), Pharmacogenet基因组学. 21(7):365-74.

The insertion of two amino acids into a transcriptional inducer converts it into a galactokinase.

李建军，李建军，李建军，(2000)， 美国国家科学院院刊 97 (7): 3154-3159.

The yeast galactose genetic switch is mediated by formation of a Gal4p/Gal80p/Gal3p complex.

李志强，(1998); EMBO杂志 17 (14): 4086-4091

Nitrogen metabolite repression involves the C-terminus and the GATA domain of the Aspergillus transcription factor AREA and the 3'-untranslated region of its mRNA.

普拉特一, Langdon T, Arst HN, Kirk D, Tollervey D, Mates Sanchez JM, Caddick MX, (1996), EMBO杂志 15 (11): 2791-2801.

Veeva ID: Z4-51856
编制日期:2023年1月